Aperture

Neuromuscular · Rare

Duchenne muscular dystrophy

Updated August 2026 · DMD (dystrophin, Xp21)

← Pipeline

Avidity / Novartis · ASO / exon skip · Filed / review

del-zota (AOC 1044)

Thesis

The first serious test of whether better delivery can make exon skipping matter. Exon 44 is a smaller slice (~6%) but a clean beachhead. The Novartis bid is the tell: Big Pharma is buying the platform, not a 6% franchise.

Probability of success

62%

Range 45–75%

  • Dystrophin step-change vs PMO▲ High
  • Narrow genotype (ex44 only at launch)▼ Med
  • Strategic owner (Novartis) for global access▲ High
  • Class residual scepticism on skippers▼ Med

Time to market

BLA 2026 → US 2026/27; EU follows

  • 2026BLA filing
  • 2026–27US decision
  • Close of Novartis/AvidityOwner and resourcing

Peak revenue (US+EU+JP dir.)

$700M

$350M – $1.2B

Peak build

  • ex44 prevalent treated 7MM~1,400 diagnosed
  • Peak share of amenable45–60% if dystrophin is clearly better
  • Net pricePMO-like or modest premium, less frequent dosing
  • UpsideAOC platform expansion to 51/53/45 is the real equity story

What kills the number

  • If dystrophin is only incrementally better, this is a $300M orphan, not a platform proof.
  • Deal timing / FTC on the Novartis bid.